Metabolic effects of ursodeoxycholic acid in patients with non-alcoholic fatty liver disease
https://doi.org/10.51793/OS.2024.27.4.010
Abstract
Background. Nonalcoholic fatty liver disease is by far the most common chronic liver disease worldwide with a global prevalence of 32.4%. Currently, there is an active search for new therapeutic options for the management of patients with nonalcoholic fatty liver disease. At the same time, there is a process of rethinking the effect of known drugs, in particular ursodeoxycholic acid, from the perspective of new points of therapeutic application, including the metabolic effects of this drug. Ursodeoxycholic acid is a naturally occurring hydrophilic non-cytotoxic bile acid that is present normally in bile, occupying 3-5% of the bile acid pool. Ursodeoxycholic acid is currently a drug with multiple therapeutic effects, which is actively used in the treatment of one non-alcoholic fatty liver disease. The article focuses on the effect of ursodeoxycholic acid on lipid, carbohydrate metabolism, and insulin resistance in patients with nonalcoholic fatty liver disease. Special attention is paid to the effect of ursodeoxycholic acid on the state of the intestinal microbiota and the maintenance of the integrity of the intestinal barrier as a factor in the progression of metabolic disorders in non-alcoholic fatty liver disease.
Results. The data of modern literature convincingly show that the most researched, available in clinical practice and reasonable approach to the treatment of nonalcoholic fatty liver disease is the use of ursodeoxycholic acid. The evidence-based advantages of the original ursodeoxycholic acid drug in the correction of metabolic disorders in patients with non-alcoholic fatty liver disease have been noted.
About the Author
V. A. Akhmedov
Omsk State Medical University
Россия
Россия
Vadim A. Akhmedov, Dr. of Sci. (Med.) Professor, Head of the Department of Medical Rehabilitation of Additional Professional Education
5 Petr Nekrasov str., Omsk
References
1. Ding X., He X., Tang B., et al. Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies. Chin Med. 2024; 19 (1): 21. DOI: 10.1186/s13020-024-00894-1.
2. Pathil A., Mueller J., Warth A., et al. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and infammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012; 55 (5): 1369-1378. DOI: 10.1002/hep.25531.
3. Castro R. E., Ferreira D. M. S., Afonso M. B., et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human nonalcoholic fatty liver disease. J Hepatol. 2013; 58 (1): 119-125. DOI: 10.1016/j.jhep.2012.08.008.
4. Li H., Wang Q. L., Chen P. Z., et al. Ursodeoxycholic acid treatment restores gut microbiota and alleviates liver infammation in non-alcoholic steatohepatitic mouse model. Front Pharmacol. 2021; 12: 788558. doi.org/10.3389/fphar.2021.788558.
5. Nadinskaia M., Maevskaya M., Ivashkin V., et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver f brosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021; 27 (10): 959-975. DOI: 10.3748/wjg.v27.i10.959.
6. Rasskazova M. A., Vorobyev S. V., Butova H. N. Possibilities for the use of ursodeoxycholic acid in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. Terapevticheskii Arkhiv. 2023; 95 (4): 316-321. DOI: 10.26442/00403660.2023.04.2021 25. (In Russ.)
7. Wu M., Zha M., Lv Q., et al. Non-alcoholic fatty liver disease and stroke: A Mendelian randomization study. Eur J Neurol. 2022; 29 (5): 1534-1537. DOI: 10.1111/ene.15277.
8. Zhang F., Deng Y., Wang H., et al. Gut microbiota-mediated ursodeoxycholic acids regulate the inflammation of microglia through TGR5 signaling after MCAO. Brain Behav Immun. 2024; 115: 667-679. DOI: 10.1016/j.bbi.2023.11.021.
9. Guo X., Wang J., Xu H., et al. Obesity induced disruption on diurnal rhythm of insulin sensitivity via gut microbiome-bile acid metabolism. Biochim Biophys Acta Mol Cell Biol Lipids. 2024; 1869 (1): 159419. DOI: 10.1016/j.bbalip.2023.159419. 10. Vachliotis I. D., Polyzos S. A. The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Curr Obes Rep. 2023; 12 (3): 191-206. DOI: 10.1007/s13679-023-00519-y.
10. Guman M. S. S., Haal S., Acherman Y. I. Z., et al. Ursodeoxycholic Acid Use After Bariatric Surgery: Effects on Metabolic and Inflammatory Blood Markers. Obes Surg. 2023; 33 (6): 1773-1781. DOI: 10.1007/s11695-023-06581-8.
11. Marchianò S., Biagioli M., Roselli R., et al. Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling. Biochim Biophys Acta Mol Cell Biol Lipids. 2022; 1867 (11): 159218. DOI: 10.1016/j.bbalip.2022.159218.
12. Ivachevska V. V. The effect of comprehensive treatment of patients with non-alcoholic fatty liver disease in combination with prediabetes on the lipid profile. Wiad Lek. 2021; 74 (4): 957-760.
13. Wu P., Zhao J., Guo Y., et al. Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK. Biochem Biophys Res Commun. 2020; 529 (3): 834-838. DOI: 10.1016/j.bbrc.2020.05.128.
14. Gheibi S., Gouvarchin Ghaleh H. E., Motlagh B. M., et al. Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease. Biomed Pharmacother. 2019; 115: 108938. DOI: 10.1016/j.biopha.2019.108938
15. Simental-Mendía L. E., Simental-Mendía M., Sánchez-García A., et al. Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and metaanalysis of randomized placebo-controlled trials. Lipids Health Dis. 2019; 18 (1): 88. DOI: 10.1186/s12944-019-1041-4.
16. Hu J., Hong W., Yao K. N., et al. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/ mTOR/SREBP-1 signaling pathway. World J Gastroenterol. 2019; 25 (12): 1492-1501. DOI: 10.3748/wjg.v25.i12.1492.
17. Chen Y. S., Liu H. M., Lee T. Y. Ursodeoxycholic Acid Regulates Hepatic Energy Homeostasis and White Adipose Tissue Macrophages Polarization in LeptinDeficiency Obese Mice. Cells. 2019; 8 (3): 253. DOI: 10.3390/cells8030253.
18. Sánchez-García A., Sahebkar A., SimentalMendía M., et al.Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2018; 135: 144-149. DOI: 10.1016/j.phrs.2018.08.008.
19. Abdel-Ghaffar A., Ghanem H. M., Ahmed E. K., et al. Ursodeoxycholic acid suppresses the formation of fructose/streptozotocin-induced diabetic cataract in rats. Fundam Clin Pharmacol. 2018; 32 (6): 627-640. DOI: 10.1111/fcp.12385.
20. Akhmedov V. A., Gaus O. V. Intestinal microbiota and the risk of obesity and nonalcoholic fatty liver disease. Study guide. Moscow: 2020, Prima Print. 88 p. (In Russ.)
21. Li H., Wang Q., Chen P., et al. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in NonAlcoholic Steatohepatitic Mouse Model. Front Pharmacol. 2021; 12: 788558. DOI: 10.3389/fphar.2021.788558.
22. Trampert D. C., Kunst R. F., van de Graaf S. F. Targeting bile salt homeostasis in biliary diseases. J.Curr Opin Gastroenterol. 2024; 40 (2): 62-69. DOI: 10.1097/MOG.0000000000000997.
23. Yokoyama K., Tatsumi Y., Hayashi K., et al. Effects of Ursodeoxycholic Acid and Insulin on Palmitate-Induced ROS Production and Down-Regulation of PI3K/Akt Signaling Activity. Biol Pharm Bull. 2017; 40 (11): 2001- 2004. DOI: 10.1248/bpb.b17-00423.
24. Elhini S. H., Wahsh E. A., Elberry A. A., et al. The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals (Basel). 2022; 15 (12): 1516. DOI: 10.3390/ph15121516.
25. Setchell K. D., Galzigna L., O'Connell N., et al. Bioequivalence of a new liquid formulation of ursodeoxycholic acid (Ursofalk suspension) and Ursofalk capsules measured by plasma pharmacokinetics and biliary enrichment. Aliment Pharmacol Ther. 2005; 21 (6): 709-721. DOI: 10.1111/j.1365-2036.2005.02385.x.
26. Hlynov I. B., Akimenko R. I., Gurikova I. A., et al. Biliary sludge: therapeutic experience in the real clinical practice. Lechaschi Vrach. 2019; 4: 80-83. (In Russ.)
Review
For citations:
Akhmedov V.A. Metabolic effects of ursodeoxycholic acid in patients with non-alcoholic fatty liver disease. Lechaschi Vrach. 2024;(4):71-76. (In Russ.) https://doi.org/10.51793/OS.2024.27.4.010
Views:
133
JATS XML
Email this article 
